Format

Send to

Choose Destination
J Intern Med. 2018 Jun;283(6):544-557. doi: 10.1111/joim.12737. Epub 2018 Mar 15.

Metabolomic response to coffee consumption: application to a three-stage clinical trial.

Author information

1
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
2
Genomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland.
3
Metabolon Inc., Durham, NC, USA.
4
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
5
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
6
Biosystems Data Analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
7
Centre for Human Metabolomics, Faculty of Natural Sciences, North-West University, Potchefstroom, South Africa.
8
Dasman Diabetes Institute, Dasman, Kuwait.
9
Department of Neuroscience and Preventive Medicine, Danube-University Krems, Krems, Austria.
10
Disease Risk Unit, National Institute for Health and Welfare, Helsinki, Finland.
11
Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

Abstract

BACKGROUND:

Coffee is widely consumed and contains many bioactive compounds, any of which may impact pathways related to disease development.

OBJECTIVE:

To identify individual metabolite changes in response to coffee.

METHODS:

We profiled the metabolome of fasting serum samples collected from a previously reported single-blinded, three-stage clinical trial. Forty-seven habitual coffee consumers refrained from drinking coffee for 1 month, consumed four cups of coffee/day in the second month and eight cups/day in the third month. Samples collected after each coffee stage were subject to nontargeted metabolomic profiling using UPLC-ESI-MS/MS. A total of 733 metabolites were included for univariate and multivariate analyses.

RESULTS:

A total of 115 metabolites were significantly associated with coffee intake (P < 0.05 and Q < 0.05). Eighty-two were of known identity and mapped to one of 33 predefined biological pathways. We observed a significant enrichment of metabolite members of five pathways (P < 0.05): (i) xanthine metabolism: includes caffeine metabolites, (ii) benzoate metabolism: reflects polyphenol metabolite products of gut microbiota metabolism, (iii) steroid: novel but may reflect phytosterol content of coffee, (iv) fatty acid metabolism (acylcholine): novel link to coffee and (v) endocannabinoid: novel link to coffee.

CONCLUSIONS:

The novel metabolites and candidate pathways we have identified may provide new insight into the mechanisms by which coffee may be exerting its health effects.

KEYWORDS:

biomarkers; caffeine; coffee; metabolomics; trial

PMID:
29381822
DOI:
10.1111/joim.12737

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center